Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Kaposi Sarcoma, Sarcoma, Kaposi
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Classic Kaposi sarcoma (KS), as well as endemic KS in adult patients, is usually limited to the skin and has an indolent course. Thus, management for both is typically similar. Patients are predisposed to develop a second primary malignancy, and the treating physician should consider this factor when arranging a schedule of follow-up treatment for the patient.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Treatment options for localized skin disease include (options are equivalent):
Radiation therapy.
Sources: Radiation therapy
Surgery.
Sources: Surgery
Other options (cryo-laser, intralesional, and topical therapy).
Sources: Other options (cryo-laser, intralesional, and topical therapy)
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
For solitary lesions or lesions of limited extent, modest doses of radiation applied with a limited margin provide excellent control of disease in the treated area. Usually, superficial radiation beams, such as electron beams, are used. Some authors believe disease recurrence in adjacent untreated skin is common if only involved-field radiation therapy is used and claim better cure rates when extended-field radiation therapy is used.[1]
Sources: 1
For low-voltage (100 kv) photon radiation therapy, 8 Gy to 10 Gy is given as a single dose or 15 Gy to 20 Gy is given over 1 week because solitary lesions control nearly 100% of local disease, but recurrence in adjacent areas is common.
For electron-beam radiation therapy (EBRT), 4 Gy is given once weekly for 6 to 8 consecutive weeks with a 4-MeV to 6-MeV electron beam. Ports should include the entire skin surface 15 cm above the lesion.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Surgical excision may benefit patients with small superficial lesions, but local recurrence is likely to occur. However, multiple small excisions can continue to be performed for good disease control.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Treatment options for advanced skin disease include:
Radiation therapy.
Sources: Radiation therapy
Chemotherapy.
Sources: Chemotherapy
Biological and targeted therapy.
Sources: Biological and targeted therapy
Immunotherapy.
Sources: Immunotherapy
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Modest doses can be effective in controlling widespread skin disease. The type of radiation (i.e., photon vs. electron) and fields used must be tailored to suit the distribution of disease in the individual patient.[1] Radiation therapy options include:
Sources: 1
Extended-field EBRT.
For disease limited to areas distal to the knee, subtotal-skin EBRT directed to skin below the umbilicus.
For disease that extends above the knee, total-skin EBRT.EBRT used in this manner gave long-term results that were superior to those obtained with radiation therapy administered to successive individual lesions as they appeared.[4]
Sources: 4
For extensive disease, EBRT 4 Gy given once weekly for 6 to 8 consecutive weeks, and subtotal- or total-skin radiation therapy.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Because classic KS is such a rare disease in the United States, and is usually treated initially with radiation therapy, few patients have been treated with chemotherapy. Its use in classic KS is based on data extrapolated from treatment of AIDS-associated KS, and no randomized prospective trials have compared one agent with another in classic KS. The agents listed below have potential benefit.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Evidence (PLD):
A multicenter trial included 55 patients with classic KS who were treated over a decade.[5]
Sources: 5
A multicenter trial included 55 patients with classic KS who were treated over a decade.[5]
A 71% overall response rate was seen using PLD, with a median response duration of 25 months.[5][Level of evidence C3]
Sources: 5 · Level of evidence C3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Paclitaxel has shown activity in both AIDS-associated and classic KS in small case series.[9-12]
Evidence (taxanes):
A small trial included 73 patients with AIDS-associated KS (32% had an undetectable HIV viral load). Patients were randomly assigned to receive either PLD or paclitaxel.[9]
Sources: 9
A small trial included 73 patients with AIDS-associated KS (32% had an undetectable HIV viral load). Patients were randomly assigned to receive either PLD or paclitaxel.[9]
Response rates were 46% for patients who received PLD and 56% for patients who received paclitaxel. The median progression-free survival (PFS) was 12 months for patients who received PLD and 18 months for patients who received paclitaxel. The 2-year overall survival rates were 78% for patients who received PLD and 79% for patients who received paclitaxel.[9][Level of evidence B3]
Sources: 9 · Level of evidence B3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Single-agent vinblastine [13-16], oral etoposide [17-19], and gemcitabine [20-22] have all shown good activity in classic and AIDS-associated KS.
Evidence (other chemotherapy agents):
A phase III trial included 65 patients with classic KS. Patients were randomly assigned to receive either oral etoposide or vinblastine.[18]
Sources: 18
A phase III trial included 65 patients with classic KS. Patients were randomly assigned to receive either oral etoposide or vinblastine.[18]
Response rates were relatively high and did not significantly differ (58% for patients who received PLD and 74% for patients who received paclitaxel).[18][Level of evidence B3]
Sources: 18 · Level of evidence B3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Agents that modulate the immune system, such as imide drugs and interferon alfa-2b, have shown efficacy in both classic and AIDS-associated KS.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
The U.S. Food and Drug Administration (FDA) approved pomalidomide for the treatment of KS in patients with and without HIV.
Evidence (pomalidomide):
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
Sources: 23
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
The overall response rate was 71%, and 80% among patients without HIV. The median PFS was 10 months.[23]
Sources: 23
Pomalidomide was generally well tolerated. Common adverse events included neutropenia, anemia, fatigue, constipation, and rash. There were few grade 3 events (neutropenia, infection, and edema).[24]
Sources: 24
Pomalidomide is teratogenic, prescribed through a Risk Evaluation and Mitigation Strategy (REMS) program, and it should be given with aspirin to mitigate venous thromboembolism risk.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
The FDA approved interferon alfa-2b for the treatment of AIDS-associated KS. It is sometimes used off-label for classic KS.
Evidence (interferon alfa-2b):
A small case series included 16 patients without HIV.[25]
Sources: 25
A small case series included 16 patients without HIV.[25]
Treatment with interferon alfa-2b led to a response in ten patients (one complete response [CR], nine partial responses [PRs]).
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Immune checkpoint inhibitor therapy has been tested in classic KS and yielded promising results.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Evidence (pembrolizumab monotherapy):
Pembrolizumab monotherapy (given every 3 weeks for up to 6 months) was evaluated in a multicenter, single-arm, phase II study of 17 patients. Eight patients had classic KS and nine patients had endemic KS.[26][Level of evidence C3]
Sources: 26 · Level of evidence C3
Pembrolizumab monotherapy (given every 3 weeks for up to 6 months) was evaluated in a multicenter, single-arm, phase II study of 17 patients. Eight patients had classic KS and nine patients had endemic KS.[26][Level of evidence C3]
At a median follow-up of 20.4 months, with 88% of patients completing 6 months of treatment, the best overall response rate was 71% (12% with CR, 59% with PR). An additional 29% of patients had stable disease based on AIDS Clinical Trials Group response evaluation.
The median time to response was 5 months (interquartile range, 3.4–12), the estimated median duration of response was 23 months (95% confidence interval [CI], 21.2–not reached [NR]), and the median time to progression (TTP) was 24 months (95% CI, 15–NR).
Sixty-four percent (7 of 11) of pretreated patients and 83% (5 of 6) of chemotherapy-naïve patients had a CR or PR.
Pembrolizumab was generally well tolerated. Two patients (12%) had grade 3 events: acute cardiac decompensation and granulomatous reaction in the lung. Two patients discontinued treatment due to grade 2 pancreatitis and grade 3 acute cardiac decompensation, respectively.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Evidence (ipilimumab and nivolumab):
Ipilimumab and nivolumab combination therapy was evaluated in a phase II study of 18 patients with refractory classic KS. Patients received nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression, for up to 24 months.[27]
Sources: 27
Ipilimumab and nivolumab combination therapy was evaluated in a phase II study of 18 patients with refractory classic KS. Patients received nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until disease progression, for up to 24 months.[27]
At a median follow-up of 24.4 months, the overall response rate was 87% by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. The 6- and 12-month PFS rates were 77% and 59%, respectively.[27][Level of evidence B4]
Sources: 27 · Level of evidence B4
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Treatment of AIDS-associated Kaposi sarcoma (KS) may result in the following:
The disappearance or reduction in size of specific skin lesions, thereby alleviating the discomfort associated with the chronic edema and ulcerations that often accompany multiple skin tumors seen on the lower extremities.
Control of symptoms associated with mucosal or visceral lesions.
No data are available to show that treatment improves survival.[1] In addition to antitumor treatment, essential components of an optimal KS treatment strategy in this population include antiretroviral treatment, prophylaxis for opportunistic infections, and rapid recognition and treatment of intercurrent infections. Therefore, close collaboration between oncologists and HIV specialists is vital.
Sources: 1
Most patients with good-risk disease, defined by the AIDS Clinical Trials Group as T0, show tumor regression with antiretroviral therapy alone.[2-4] Patients with poor-risk disease, defined as T1, usually require a combination of antiretroviral therapy and chemotherapy with discontinuation of the chemotherapy after disappearance of the skin lesion.[2-4]
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Treatment options for AIDS-associated KS include:
Local modalities.
Sources: Local modalities
Chemotherapy.
Sources: Chemotherapy
Biological and targeted therapy.
Sources: Biological and targeted therapy
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Small localized lesions of KS may be treated by electrodesiccation and curettage, cryotherapy, or by surgical excision. KS tumors are also generally very responsive to local radiation therapy, and excellent palliation has been obtained with doses at 20 Gy or slightly higher.[5,6] Radiation therapy is generally reserved to treat localized areas of the skin and oral cavity. It is used less often to control pulmonary, gastrointestinal tract, or other sites of KS lesions. Localized KS lesions have also been effectively treated with intralesional injections of vinblastine.[7] Alitretinoin 0.1% gel provided local control in a randomized, prospective, multicenter trial.[8][Level of evidence B3]
Sources: 5 · 6 · 7 · 8 · Level of evidence B3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
In AIDS-associated KS, the already profoundly depressed immunologic status of the patient limits the therapeutic usefulness of systemic chemotherapy. Systemic chemotherapy studies in patients with AIDS-associated KS have used doxorubicin, bleomycin, vinblastine, vincristine, etoposide, paclitaxel, and docetaxel alone or in combination.[9-13][Level of evidence C3] The combination of antiretroviral therapy and liposomal doxorubicin resulted in a 5-year overall survival rate of 85% in 140 patients with T1 disease.[3][Level of evidence C3]
Sources: 9 · 13 · Level of evidence C3 · 3 · Level of evidence C3
Randomized multicenter trials showed an improvement in response rate (45%–60% vs. 20%–25%) and a more favorable toxic effects profile for pegylated liposomal doxorubicin (PLD) or liposomal daunorubicin, compared with the combination of doxorubicin, bleomycin, and vincristine or bleomycin and vincristine.[14-16][Level of evidence B3] During antiretroviral therapy, both PLD and paclitaxel are active single agents with response rates close to 50%.[17][Level of evidence B3]
Sources: 14 · 16 · Level of evidence B3 · 17 · Level of evidence B3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
The interferon alfas have also been widely studied and show a 40% objective response rate in patients with AIDS-associated KS.[18,19] In these reports, the responses differed significantly according to the following prognostic factors:
Extent of disease.
Prior or coexistent opportunistic infections.
Prior treatment with chemotherapy.
CD4 lymphocyte counts lower than 200 cells/µL.
Presence of circulating acid-labile interferon alfa.
Increase in beta-2-microglobulin.
Several treatment studies have combined interferon alfa with other chemotherapeutic agents. Overall, these trials have shown no benefit with the interferon-chemotherapy combinations as compared with the single-agent activities.
Recombinant interferon alfa-2a and recombinant interferon alfa-2b were the first agents approved for the treatment of KS. Approval was based on single-agent studies performed in the 1980s before the advent of antiretroviral therapy. The early studies demonstrated improved efficacy at relatively high doses.
High-dose monotherapy is rarely used today, and instead, interferon is given in combination with other anti-HIV drugs in doses of 4 to 18 million units. Neutropenia is dose limiting, and trials of doses of 1 to 10 million units combined with less myelosuppressive antiretroviral agents are in progress. Response to interferon is slow, and the maximum effect is seen after 6 or more months. Interferon should probably not be used to treat patients with rapidly progressive, symptomatic KS.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Imatinib is a c-kit/platelet-derived growth factor receptor inhibitor.
Evidence (imatinib):
A phase II trial included 30 patients with AIDS-associated KS.[20]
Sources: 20
A phase II trial included 30 patients with AIDS-associated KS.[20]
A partial response (PR) was seen in 10 of 30 previously treated patients . Previous treatment included antiretroviral therapy and chemotherapy.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Bevacizumab is a humanized, anti–vascular endothelial growth factor monoclonal antibody.
Evidence (bevacizumab):
A phase II study included 16 assessable patients with KS and HIV. Patients received bevacizumab intravenously (IV) on days 1 and 8 and then every 3 weeks.[21]
Sources: 21
A phase II study included 16 assessable patients with KS and HIV. Patients received bevacizumab intravenously (IV) on days 1 and 8 and then every 3 weeks.[21]
There was a response in 5 of 16 patients. These patients had not improved after prior antiretroviral therapy and chemotherapy.[21][Level of evidence C3]
Sources: 21 · Level of evidence C3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Evidence (interleukin-12):
A phase I and phase II trial included 24 evaluable patients. Patients received interleukin-12 subcutaneously twice weekly.[22]
Sources: 22
A phase I and phase II trial included 24 evaluable patients. Patients received interleukin-12 subcutaneously twice weekly.[22]
Treatment resulted in a response rate of 71% (95% confidence interval, 48%–89%).[22][Level of evidence C3]
Sources: 22 · Level of evidence C3
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
The U.S. Food and Drug Administration approved pomalidomide for patients with AIDS-associated KS.
Evidence (pomalidomide):
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
Sources: 23
A phase I/II study of pomalidomide included 28 patients with KS. Ten patients were HIV-positive and 18 patients were HIV-negative.[23]
The overall response rate was 71%, and 80% among patients without HIV. The median progression-free survival was 10 months.[23]
Sources: 23
Pomalidomide was generally well tolerated. Common adverse events included neutropenia, anemia, fatigue, constipation, and rash. There were few grade 3 events (neutropenia, infection, and edema).[24]
Sources: 24
Pomalidomide is teratogenic, prescribed through a Risk Evaluation and Mitigation Strategy (REMS) program, and it should be given with aspirin to mitigate venous thromboembolism risk.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Evidence (bortezomib):
Bortezomib was evaluated in a small phase I dose-escalation study of 17 patients with AIDS-associated KS. Patients received bortezomib IV on days 1, 8, and 15 of 28-day cycles.[25]
Sources: 25
Bortezomib was evaluated in a small phase I dose-escalation study of 17 patients with AIDS-associated KS. Patients received bortezomib IV on days 1, 8, and 15 of 28-day cycles.[25]
Bortezomib was relatively well tolerated and led to a PR in 60% of all evaluable patients. Among those receiving the highest bortezomib dose, 83% of patients had a PR and 17% had stable disease.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Immune reconstitution inflammatory syndrome (IRIS) is a hyperimmune response in patients with HIV/AIDS within the first 6 months of starting antiretroviral therapy. Kaposi sarcoma (KS)-associated IRIS (KS-IRIS) is not well-defined, but is considered to be the sudden clinical worsening of previous KS ("paradoxical") or the new presentation of KS (“unmasked”) in close proximity to starting or modifying antiretroviral therapy.[26]
Sources: 26
Estimates for KS-IRIS incidence vary from 2% to 39%, with the highest risk in patients with any of the following characteristics:[26,27]
High HIV viral loads (>10,000 copies/mL).
CD4 lymphocyte count less than 200 cells/µL.
Detectable plasma human herpesvirus 8 DNA.
Pulmonary KS involvement.
Recent steroid use.
KS-IRIS typically presents with increased swelling/tenderness of lesions, new or worsening edema, and visceral or pulmonary involvement.
Management of KS-IRIS typically includes continuing antiretroviral therapy and initiating systemic treatment, such as liposomal doxorubicin or paclitaxel, for KS. The evidence for use of chemotherapy to prevent KS-IRIS is mixed, but can be considered on an individual basis.[26] Glucocorticoids are avoided due to the risk of dramatic worsening of KS.[27,28] Thalidomide has also been used for steroid-refractory IRIS.[29]
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
Source: Kaposi Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 7, 2025. Captured 2026-09-09.
In general, transplant-related Kaposi sarcoma is effectively managed by reduction in immunosuppression and does not require systemic treatment. Transitioning immunosuppression therapy to an mTOR inhibitor, such as sirolimus, has demonstrated efficacy in small studies and can be considered.[1]
Sources: 1
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
HAART is a combination of several drugs used to lessen the damage to the immune system caused by HIV infection. Treatment with HAART reduces the risk of epidemic Kaposi sarcoma, although it is possible for a person to develop epidemic Kaposi sarcoma while taking HAART.
For information about AIDS and its treatment, see the HIVinfo website.
Sources: HIVinfo website
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
There are different types of treatment for patients with Kaposi sarcoma.
The following types of treatment are used to treat Kaposi sarcoma:
The following types of treatment are used to treat Kaposi sarcoma:
HAART
Radiation therapy
Surgery
Cryosurgery
Chemotherapy
Immunotherapy
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Targeted therapy
Treatment for Kaposi sarcoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Different types of treatments are available for patients with Kaposi sarcoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: Kaposi sarcoma · standard · clinical trials · research study · cancer
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Treatment of epidemic Kaposi sarcoma combines treatment for Kaposi sarcoma with treatment for acquired immunodeficiency syndrome (AIDS). The types of treatment used to treat Kaposi sarcoma include:
Sources: acquired immunodeficiency syndrome
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Highly active antiretroviral therapy (HAART) is a combination of several drugs used to lessen the damage to the immune system caused by human immunodeficiency virus (HIV) infection. For many patients, HAART alone may be enough to treat epidemic Kaposi sarcoma. For other patients, HAART may be combined with other standard treatments to treat epidemic Kaposi sarcoma.
Sources: Highly active antiretroviral therapy · drugs · immune system · human immunodeficiency virus
For information about AIDS and its treatment, see the HIVinfo website.
Sources: HIVinfo website
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
Sources: Radiation therapy · x-rays · radiation · cells
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: External radiation therapy
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
The way the radiation therapy is given depends on the type of the cancer being treated. Certain types of external radiation therapy are used to treat Kaposi sarcoma lesions. Photon radiation therapy treats lesions with high-energy light. Electron beam radiation therapy uses tiny negatively charged particles called electrons.
Sources: lesions · Photon radiation therapy · Electron beam · electrons
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
The following surgical procedures may be used for Kaposi sarcoma to treat small, surface lesions:
Sources: surgical
Local excision: The cancer is cut from the skin along with a small amount of normal tissue around it.
Electrodesiccation and curettage: The tumor is cut from the skin with a curette (a sharp, spoon-shaped tool). A needle-shaped electrode is then used to treat the area with an electric current that stops the bleeding and destroys cancer cells that remain around the edge of the wound. The process may be repeated one to three times during the surgery to remove all of the cancer.
Sources: Electrodesiccation · curettage · tumor · curette · electrode · wound
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Cryosurgery is a treatment that uses an instrument to freeze and destroy abnormal tissue. This type of treatment is also called cryotherapy.
Sources: Cryosurgery · abnormal
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, tissue, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).
Sources: Chemotherapy · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · abdomen · regional chemotherapy
In electrochemotherapy, intravenous chemotherapy is given and a probe is used to send electric pulses to the tumor. The pulses make an opening in the membrane around the tumor cell and allow the chemotherapy to get inside.
Sources: intravenous chemotherapy · membrane
The way the chemotherapy is given depends on where the Kaposi sarcoma lesions occur in the body. In Kaposi sarcoma, chemotherapy may be given in the following ways:
For local Kaposi sarcoma lesions, such as in the mouth, anticancer drugs may be injected directly into the lesion (intralesional chemotherapy).
Sources: local · intralesional
For local lesions on the skin, a topical agent may be applied to the skin as a gel. Electrochemotherapy may also be used.
Sources: topical
For widespread lesions on the skin, intravenous chemotherapy may be given.
Liposomal chemotherapy uses liposomes (very tiny fat particles) to carry anticancer drugs. Liposomal doxorubicin is used to treat Kaposi sarcoma. The liposomes build up in Kaposi sarcoma tissue more than in healthy tissue, and the doxorubicin is released slowly. This increases the effect of the doxorubicin and causes less damage to healthy tissue.
Sources: Liposomal · Liposomal doxorubicin
See Drugs Approved for Kaposi Sarcoma for more information.
Sources: Drugs Approved for Kaposi Sarcoma
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. Immunotherapy with interferon alfa and interleukin-12 may be used to treat Kaposi sarcoma.
Sources: Immunotherapy · interferon alfa · interleukin-12
See Drugs Approved for Kaposi Sarcoma for more information.
Sources: Drugs Approved for Kaposi Sarcoma
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Monoclonal antibody therapy and tyrosine kinase inhibitors (TKIs) are types of targeted therapy being studied in the treatment of Kaposi sarcoma.
Sources: Targeted therapy · Monoclonal antibody · therapy · tyrosine kinase inhibitors
Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells. Bevacizumab is a monoclonal antibody that may be used to treat Kaposi sarcoma.
Sources: proteins · antibodies · infusion · toxins · Bevacizumab
TKIs block signals needed for tumors to grow. Imatinib mesylate is a TKI that may be used to treat Kaposi sarcoma.
Sources: Imatinib mesylate
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment for single skin lesions may include the following:
Sources: lesions
Radiation therapy.
Sources: Radiation therapy
Surgery.
Sources: Surgery
Treatment for skin lesions all over the body may include the following:
Radiation therapy.
Chemotherapy.
Sources: Chemotherapy
Electrochemotherapy.
Treatment for Kaposi sarcoma that affects lymph nodes or the gastrointestinal tract usually includes chemotherapy with or without radiation therapy.
Sources: Kaposi sarcoma · lymph nodes · gastrointestinal tract
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Kaposi Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 17, 2023. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment for epidemic Kaposi sarcoma may include the following:
Sources: Kaposi sarcoma
HAART.
Sources: HAART
Surgery, including local excision or electrodesiccation and curettage.
Sources: Surgery · excision · electrodesiccation · curettage
Cryosurgery.
Sources: Cryosurgery
Radiation therapy.
Sources: Radiation therapy
Chemotherapy using one or more anticancer drugs.
Sources: Chemotherapy · drugs
Immunotherapy using interferon alfa or interleukin-12.
Sources: Immunotherapy · interferon alfa · interleukin-12
Targeted therapy using imatinib or bevacizumab.
Sources: Targeted therapy · imatinib · bevacizumab
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Kaposi Sarcoma, Sarcoma, Kaposi
ClinicalTrials.gov recordTreatment Options for Advanced Classic and Endemic Kaposi Sarcoma
1.2 AIDS-Related Kaposi’s Sarcoma DOXIL liposomal infusion is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.
Kaposi Sarcoma
Treatment Options for Localized Classic and Endemic Kaposi Sarcoma
• with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative.
• Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART).
POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a...
DailyMed label